Pro Medicus Ltd (ASX: PME) shares are marching higher today.
Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed on Friday trading for $301.77. In late morning trade on Monday, shares are changing hands for $305.02, up 1.1%.
For some context, the ASX 200 is up 0.6% at this same time.
This sees Pro Medicus shares up 71.0% in a year. And investors who bought at the recent 52-week lows on 7 April will already have seen gains of 72.5%.
Here's what's happening with the healthcare company today amid the latest tariff announcements from United States President Donald Trump.
Image source: Getty Images
Pro Medicus shares aim to dodge US tariffs
If you were following the markets on Friday, you'll have heard of the 100% tariffs that the US will begin imposing on pharmaceutical products imported into the nation, commencing on 1 October.
The news saw Pro Medicus shares slump 2.4% on Friday.
Exemptions will be granted for companies that have or are actively building a manufacturing plant in the US. Trump earlier defined that as already having "broken ground".
"There will, therefore, be no tariff on these pharmaceutical products if construction has started," the US President posted on social media.
Following the tariff announcement, shares in most ASX 200 healthcare stocks sold off. Shares in biotech giant CSL Ltd (ASX: CSL), for example, closed down 1.9% on Friday, while hearing implant manufacturer Cochlear Ltd (ASX: COH) saw its shares slip 1.8%.
But in an announcement that looks to be offering a boost to Pro Medicus shares this morning, the company noted that it "does not produce, sell or otherwise have any direct involvement with the pharmaceutical industry".
According to management, "As such, the company believes it is not subject to the recently announced US tariff on pharmaceuticals as alluded to in the 'making headlines' section of Friday's financial press."
What's the latest from the ASX 200 healthcare stock?
Pro Medicus shares were in sharp focus when the company reported its full-year FY 2025 results on 14 August.
Highlights included a 31.9% year-on-year increase in revenue from ordinary activities to $213.0 million.
And on the bottom line, the ASX 200 healthcare stock achieved a 40.2% increase in underlying profit before tax to $163.3 million. The company had no debt at the end of reporting period.
"All key financial metrics headed in the right direction. And importantly we continued our trajectory of strong, profitable growth," Pro Medicus CEO Sam Hupert said.
Pro Medicus shares closed up 6.2% on the day the results were released.
